📊 HALO Key Takeaways
Is Halozyme Therapeutics, Inc.. (HALO) a Good Investment?
HaloZyme demonstrates strong revenue growth of 37.6% YoY and exceptional free cash flow generation ($644.6M), but declining net income (-28.6% YoY) and EPS (-25.4% YoY) despite revenue expansion signal deteriorating profitability quality. Extremely high leverage (43.89x debt-to-equity) with minimal equity base ($48.8M) presents significant financial risk that offsets strong operational cash generation.
Revenue growth is strong and operating profitability with exceptional free cash flow conversion supports balance sheet flexibility despite heavy leverage. Liquidity and interest coverage are robust, though the YoY earnings decline and anomalously low gross margin signal mix/accounting volatility to monitor.
Why Buy Halozyme Therapeutics, Inc.. Stock? HALO Key Strengths
- Robust revenue growth at 37.6% YoY indicating strong market demand
- Exceptional free cash flow of $644.6M with 46.2% FCF margin showing quality earnings
- Excellent short-term liquidity with current ratio of 4.66x and quick ratio of 3.66x
- Strong operating income margin of 33.6% and net margin of 22.7%
- Outstanding interest coverage ratio of 104.1x indicating manageable debt service
- Strong top-line growth (+37.6% YoY) with high operating margin (33.6%)
- Exceptional free cash flow (46% margin) with minimal capex needs
- Solid liquidity (4.66x current) and very high interest coverage (104x)
HALO Stock Risks: Halozyme Therapeutics, Inc.. Investment Risks
- Profitability deterioration: net income down 28.6% YoY and EPS down 25.4% despite 37.6% revenue growth
- Extreme financial leverage with 43.89x debt-to-equity ratio and $2.1B long-term debt against only $48.8M equity
- Abnormally low gross margin of 0.4% creates structural profitability concerns and data quality questions
- Thin equity cushion ($48.8M on $2.5B total assets) limits financial flexibility and increases distress risk
- High leverage and thin equity (Debt/Equity 43.9x) raise refinancing/covenant risk
- Net income and EPS down YoY despite growth, indicating margin/expense volatility
- Extremely low reported gross margin (0.4%) suggests mix or accounting anomalies that could compress profitability if persistent
Key Metrics to Watch
- Net income and EPS trajectory - must stabilize and return to growth
- Gross margin normalization - 0.4% is unsustainable and requires investigation
- Debt reduction pace and leverage ratio trend - current 43.89x is dangerously high
- Operating cash flow sustainability - confirm $651.6M is repeatable
- Revenue growth sustainability - verify 37.6% growth rate continues
- Free cash flow (FCF) margin
- Interest coverage
Halozyme Therapeutics, Inc.. (HALO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 46.2% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 4.66x current ratio provides a solid financial cushion.
HALO Profit Margin, ROE & Profitability Analysis
HALO vs Healthcare Sector: How Halozyme Therapeutics, Inc.. Compares
How Halozyme Therapeutics, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Halozyme Therapeutics, Inc.. Stock Overvalued? HALO Valuation Analysis 2026
Based on fundamental analysis, Halozyme Therapeutics, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Halozyme Therapeutics, Inc.. Balance Sheet: HALO Debt, Cash & Liquidity
HALO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Halozyme Therapeutics, Inc..'s revenue has grown significantly by 215% over the 5-year period, indicating strong business expansion. The most recent EPS of $2.10 reflects profitable operations.
HALO Revenue Growth, EPS Growth & YoY Performance
HALO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $290.1M | $137.0M | $1.05 |
| Q2 2025 | $231.4M | $93.2M | $0.72 |
| Q1 2025 | $195.9M | $76.8M | $0.60 |
| Q3 2024 | $216.0M | $81.8M | $0.61 |
| Q2 2024 | $221.0M | $74.8M | $0.56 |
| Q1 2024 | $162.1M | $39.6M | $0.29 |
| Q3 2023 | $209.0M | $61.6M | $0.44 |
| Q2 2023 | $152.4M | $22.7M | $0.16 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Halozyme Therapeutics, Inc.. Dividends, Buybacks & Capital Allocation
HALO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Halozyme Therapeutics, Inc.. (CIK: 0001159036)
📋 Recent SEC Filings
❓ Frequently Asked Questions about HALO
What is the AI rating for HALO?
Halozyme Therapeutics, Inc.. (HALO) has a Combined AI Rating of BUY from Claude (HOLD) and ChatGPT (BUY) with 64% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are HALO's key strengths?
Claude: Robust revenue growth at 37.6% YoY indicating strong market demand. Exceptional free cash flow of $644.6M with 46.2% FCF margin showing quality earnings. ChatGPT: Strong top-line growth (+37.6% YoY) with high operating margin (33.6%). Exceptional free cash flow (46% margin) with minimal capex needs.
What are the risks of investing in HALO?
Claude: Profitability deterioration: net income down 28.6% YoY and EPS down 25.4% despite 37.6% revenue growth. Extreme financial leverage with 43.89x debt-to-equity ratio and $2.1B long-term debt against only $48.8M equity. ChatGPT: High leverage and thin equity (Debt/Equity 43.9x) raise refinancing/covenant risk. Net income and EPS down YoY despite growth, indicating margin/expense volatility.
What is HALO's revenue and growth?
Halozyme Therapeutics, Inc.. reported revenue of $1.4B.
Does HALO pay dividends?
Halozyme Therapeutics, Inc.. does not currently pay dividends.
Where can I find HALO SEC filings?
Official SEC filings for Halozyme Therapeutics, Inc.. (CIK: 0001159036) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is HALO's EPS?
Halozyme Therapeutics, Inc.. has a diluted EPS of $2.56.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is HALO a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Halozyme Therapeutics, Inc.. has a BUY rating with 64% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is HALO stock overvalued or undervalued?
Valuation metrics for HALO: ROE of 649.2% (sector avg: 15%), net margin of 22.7% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy HALO stock in 2026?
Our dual AI analysis gives Halozyme Therapeutics, Inc.. a combined BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is HALO's free cash flow?
Halozyme Therapeutics, Inc..'s operating cash flow is $651.6M, with capital expenditures of $7.0M. FCF margin is 46.2%.
How does HALO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 22.7% (avg: 12%), ROE 649.2% (avg: 15%), current ratio 4.66 (avg: 2).
Is Halozyme Therapeutics, Inc.. carrying too much debt?
HALO has a debt-to-equity ratio of 43.89x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 4.66 suggests adequate short-term liquidity.
Why is HALO's return on equity (ROE) so high?
Halozyme Therapeutics, Inc.. has a return on equity of 649.2%, significantly above the Healthcare sector average of 15%. A high ROE indicates the company is efficient at generating profits from shareholder equity. This is supported by a 22.7% net margin.